Investors / Switzerland / Pureos Bioventures
Pureos Bioventures
Venture capital · Zurich, Switzerland · Europe
Pureos Bioventures is a venture capital firm that invests in private innovative drug development companies. It focuses on the next generation of biological drugs and drug formats to advance treatments for severe diseases.
Invests inHealthcare & Biotech
In its own wordsbiotechtherapeuticsdrug developmentbiologicsoncologyantibody drug conjugates
Your fit with Pureos Bioventures
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsPureos Bioventures lists 21 checked portfolio companies on its own site and is named in 3 funding rounds, 2 of them as lead. Its most frequent entry is Series A, 67% of the companies with a known first round. Its largest theme is Healthcare & Biotech (100%). 36% of its companies are based in Switzerland. It invests most often alongside Kurma Partners, Frazier Life Sciences and RA Capital.
Counts come from funding rounds that name Pureos Bioventures, complete from mid-2025: earlier rounds appear only when they were reported later. Round amounts and full round histories are on Fundup AI.
Round figures show recent activity, not Pureos Bioventures' whole history. Rounds on record name 3 companies; its own site lists 21. Funding rounds are complete from mid-2025, so counts and the yearly trend undercount a firm that invested before then. The portfolio, themes and places come from its own site and are not affected.
Entry stage
share of companies by the stage of its first roundPureos Bioventures does not state its stages on its site, so only what it does is shown.
Show as a table
| Value | |
|---|---|
| Pre-seed | 0% |
| Seed | 0% |
| Series A | 67% |
| Series B | 33% |
| Growth | 0% |
Activity by year
rounds it joined, last 10 yearsShow as a table
| Total | Rounds it led | |
|---|---|---|
| '17 | 0 | 0 |
| '18 | 0 | 0 |
| '19 | 0 | 0 |
| '20 | 0 | 0 |
| '21 | 0 | 0 |
| '22 | 0 | 0 |
| '23 | 0 | 0 |
| '24 | 0 | 0 |
| '25 | 1 | 0 |
| '26 | 2 | 2 |
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 53th | 21 companies |
| Recent activity | 69th | 2 rounds in 12 months |
| Early stage | 54th | 0% of entries at pre-seed or seed |
| Evidence | 85th | 14% of companies confirmed by a round |
| Sector focus | 100th | 100% in its largest sector |
| Reach | 88th | 7 countries |
Invests most often with
firms sharing its portfolio companiesShow as a table
| Share | |
|---|---|
| Kurma Partners | 4 |
| Frazier Life Sciences | 3 |
| RA Capital | 3 |
| Ysios Capital | 3 |
| Adjuvant Capital | 2 |
| Advent Life Sciences | 2 |
| British International Investment | 2 |
| ClavystBio | 2 |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers21100%
- No longer answers00%
- Points to another company00%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 100% | 15% |
Co-investor network
who it backs companies with, and who they back togetherCompare Pureos Bioventures head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Recent portfolio activity
when companies last raised with Pureos Bioventures| Date | Company | Stage |
|---|---|---|
| 2 Sept 2026 | Series B Led | |
| 2 Jun 2026 | Series A Led | |
| 16 Oct 2025 | Series A |
Round details for Pureos Bioventures
Amounts, full round histories and every co-investor in Pureos Bioventures' rounds are on Fundup AI. VCinfo covers investors and their portfolios.
Portfolio
21 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| Acrivon is developing targeted therapies to improve the lives of patients. | Healthcare & Biotech | Portfolio page | ||
| Adcytherix is building an antibody-drug conjugate powerhouse to advance patient-need-driven therapies | Healthcare & Biotech | Oct 2025Series A | Page + round | |
| Alentis Therapeutics is a clinical-stage biotech company that treats cancer and reverses fibrosis by developing anti-Claudin-1 antibody-drug conjugates and monoclonal antibodies | Healthcare & Biotech | Portfolio page | ||
| Portfolio page | ||||
| AnaCardio is developing novel drugs to treat heart failure | Healthcare & Biotech | Portfolio page | ||
| Araris Biotech develops antibody-drug conjugates (ADCs) using a novel linker technology | Healthcare & Biotech | Portfolio page | ||
| BaseLaunch partners with scientists and entrepreneurs to help launch and grow biotech ventures developing cutting-edge therapeutics. | Healthcare & Biotech | Portfolio page | ||
| Callio Therapeutics is a global, clinical-stage biotechnology company developing dual-payload antibody-drug conjugates (ADCs) to address the key limitation of current therapies, resistance. | Healthcare & Biotech | Portfolio page | ||
| Citryll develops therapies to treat immune-mediated inflammatory diseases by targeting Extracellular Traps (ETs) | Healthcare & Biotech | Portfolio page | ||
| Engimmune Therapeutics develops targeted, highly potent 'off-the-shelf' soluble T-cell receptor drugs to treat solid tumour cancers. | Healthcare & Biotech | Portfolio page | ||
| Hummingbird Bioscience is developing a pipeline of next-generation antibody-based therapeutics, including ADCs, for patients who do not respond to current treatments. | Healthcare & Biotech | Portfolio page | ||
| Lava Therapeutics develops therapeutics to fight cancer using gamma delta T cells | Healthcare & Biotech | Portfolio page | ||
| Mediar Therapeutics is developing treatments for fibrotic diseases by targeting the myofibroblast cell | Healthcare & Biotech | Portfolio page | ||
| Memo Therapeutics develops therapeutic antibodies to treat viral infections and cancer. | Healthcare & Biotech | Portfolio page | ||
| MinervaX is developing a prophylactic vaccine against Group B Streptococcus | Healthcare & Biotech | Portfolio page | ||
| NovaGo Therapeutics is a clinical-stage biotech company developing human antibody therapeutics for nerve growth and regeneration. | Healthcare & Biotech | Sept 2026Series B | Page + round | |
| PulseSight Therapeutics is a clinical-stage biotech company developing disruptive, non-viral gene therapies dedicated to ophthalmology | Healthcare & Biotech | Portfolio page | ||
| Tavo Biotherapeutics is a biotech company developing novel treatments for glaucoma and retinal diseases. | Healthcare & Biotech | Jun 2026Series A | Page + round | |
| Tridek-One develops first-in-class CD31 checkpoint agonists for the treatment of auto-immune diseases | Healthcare & Biotech | Portfolio page | ||
| uniQure develops gene therapies for diseases such as Huntington's disease, temporal lobe epilepsy, and hemophilia B. | Healthcare & Biotech | Portfolio page |
About this data
site last read 5 Nov 2026- Site
- pureosbio.com
- Last read
- 5 Nov 2026
- Watching since
- 5 Nov 2026
- Rounds since
- 16 Oct 2025
- Companies checked
- 21
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get Pureos Bioventures' profile as data
Pull Pureos Bioventures' portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/pureosbio.com
# also
GET /v1/firms/pureosbio.com/portfolio
GET /v1/firms/pureosbio.com/coinvestors
GET /v1/firms/pureosbio.com/news